Press Release – New York, NY – May 18, 2026 – Sichenzia Ross Ference Carmel LLP announced that it represented E.F. Hutton & Co. as the exclusive placement agent for the recently priced $5 million public offering of XORTX Therapeutics Inc. (Nasdaq: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease.
The E.F. Hutton team was led by Anthony Salazar.
The SRFC team was led by partners Ross Carmel and Thiago Spercel, with associate Benjamin Sklar.